EBSAM
DGX icon

Eubel Brady & Suttman Asset Management’s Quest Diagnostics DGX Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-460
Closed -$59K – 139
2021
Q2 		$59K Buy
+460
New +$60.2K 0.01% 314

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's DGX Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Quest Diagnostics (DGX) in Q3 2021, closing a stake of 460 shares — an estimated $59K sold.

Eubel Brady & Suttman Asset Management first reported a position in DGX in Q2 2021 and held it in 1 quarter. The position peaked at $59K in Q2 2021. 837 funds tracked by Wall St. Rank hold DGX as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Quest Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 460 Quest Diagnostics shares in Q3 2021, an estimated $59K.
  • Eubel Brady & Suttman Asset Management first reported a position in Quest Diagnostics in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Quest Diagnostics position peaked at $59K in Q2 2021.
  • 837 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.